SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    American Cancer Society. Cancer facts and figures 2005. Atlanta: American Cancer Society; 2005.
  • 2
    Ries L, Eisner M, Kosary CL, et al. SEER Cancer Statistics Review, 1973–1999, vol. 2003. Bethesda: National Cancer Institute, 2002.
  • 3
    Morrow M. The certainties and the uncertainties of ductal carcinoma in situ. J Natl Cancer Inst. 2004; 96: 424425.
  • 4
    Solin LJ, Fourquet A, Vicini FA, et al. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys. 2001; 50: 9911002.
  • 5
    Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996; 14: 754763.
  • 6
    Khan A, Newman LA. Diagnosis and management of ductal carcinoma in situ. Curr Treat Options Oncol. 2004; 5: 131144.
  • 7
    Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004; 350: 14301441.
  • 8
    Hiramatsu H, Bornstein BA, Recht A, et al. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ. Cancer J Sci Am. 1995; 1: 55.
  • 9
    Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised Phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000; 355: 528533.
  • 10
    Nakhlis F, Morrow M. Ductal carcinoma in situ. Surg Clin North Am. 2003; 83: 821839.
  • 11
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353: 19932000.
  • 12
    Julian T, Land S, Wolmark N. NSABP B-35: a clinical trial to compare anastrazole and tamoxifen for postmenopausal patients with ductal carcinoma in situ undergoing lumpectomy with radiation therapy. Breast Dis Yearbook Q. 2003; 14: 121122.
  • 13
    Yen TW, Hunt KK, Mirza NQ, et al. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004; 100: 942949.
  • 14
    Nakhlis F, Lazarus L, Hou N, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg. 2005; 201: 688694.
  • 15
    Allred D, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24 [abstract]. Presented at: 25th Annual San Antonio Breast Cancer Symposium, December 11–14, 2002; San Antonio, Texas. Abstract 30.
  • 16
    Kuerer HM, Newman LA. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol. 2005; 23: 16981705.
  • 17
    Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23: 77037720.
  • 18
    Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998; 16: 441452.
  • 19
    Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001; 19: 22632271.
  • 20
    Fisher ER, Leeming R, Anderson S, Redmond C, Fisher B. Conservative management of intraductal carcinoma (DCIS) of the breast. Collaborating NSABP investigators. J Surg Oncol. 1991; 47: 139147.
  • 21
    Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999; 86: 429438.
  • 22
    Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003; 362: 95102.
  • 23
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479484.
  • 24
    Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer. 1999; 35: 19631973.
  • 25
    [No authors listed.] Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 351: 14511467.
  • 26
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 27
    Lazarus L, Rademaker A, Acharya S: Acceptance of tamoxifen for risk reduction in patients with ductal carcinoma in situ [abstract 188]. Proc Am Soc Clin Oncol. 2002; 21: 48a.